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The  efﬁcacy  of  sarolaner  (SimparicaTM, Zoetis)  to prevent  transmission  primarily  of Borrelia  burgdor-
feri  and  secondarily  of Anaplasma  phagocytophilum  from  infected  wild-caught  Ixodes  scapularis  to  dogs
was evaluated  in a placebo-controlled  laboratory  study.  Twenty-four  purpose-bred  laboratory  Beagles
seronegative  for  B. burgdorferi  and  A.  phagocytophilum  antibodies  were  allocated  randomly  to one of  three
treatment  groups:  placebo  administered  orally  on  Days  0 and  7, or  sarolaner  at 2 mg/kg administered
orally  on  Day 0  (28 days  prior  to tick  infestation)  or on  Day  7 (21 days  prior  to  tick  infestation).  On  Day  28,
each  dog  was infested  with  approximately  25  female  and  25  male  wild  caught  adult  I.  scapularis  that  were
determined  to  have  prevalence  of  57%  for B.  burgdorferi  and  6.7%  for A.  phagocytophilum  by PCR.  In situ
tick  counts  were  conducted  on Days  29 and  30.  On Day  33,  all ticks  were  counted  and  removed.  Acaricidal
efﬁcacy  was  calculated  based on  the reduction  of  geometric  mean  live  tick  counts  in the sarolaner-treated
groups  compared  to  the  placebo-treated  group  for each  tick count.  Blood  samples  collected  from  each  dog
on Days  27,  49,  63,  77,  91 and  104 were  tested  for the presence  of  B. burgdorferi  and  A.  phagocytophilum
antibodies  using  the  SNAP® 4Dx® Plus  Test,  and  quantitatively  assayed  for B. burgdorferi  antibodies  using
an ELISA  test.  Skin  biopsies  collected  on Day  104 were  tested  for  the  presence  of B. burgdorferi  by  bacterial
culture  and  PCR.
Geometric  mean  live  tick  counts  for  placebo-treated  dogs  were  14.8,  12.8, and  19.1 on  Days  29,  30,
and  33,  respectively.  The  percent  reductions  in  mean  live  tick  counts  at 1, 2, and  5 days  after  infestation
were  86.3%,  100%,  and  100%  for the  group  treated  with  sarolaner  21 days  prior  to infestation,  and  90.9%,
97.1%,  and 100%  for the  group  treated  with  sarolaner  28 days  prior to infestation.  Geometric  mean  live
tick  counts  for  both  sarolaner-treated  groups  were  signiﬁcantly  lower  than  those  for  the  placebo  group
on all  count  days  (P  < 0.0001).
There were  no  adverse  reactions  to treatment  with  sarolaner.  Transmission  of  B.  burgdorferi  to  all  eight
placebo-treated  dogs  was conﬁrmed  by  positive  antibody  (6  of  8 dogs),  PCR (7 of 8  dogs),  and/or  culture  (7
of 8 dogs).  Similarly,  transmission  of  A.  phagocytophilum  was  conﬁrmed  by  the presence  of antibodies  in
four  placebo-treated  dogs.  In contrast,  treatment  with  a  single  dose  of sarolaner  prevented  transmission
of  B. burgdorferi  from  infected  ticks  to dogs  infested  21  or 28  days  after  treatment  as  demonstrated
by  negative  antibody,  PCR,  and  culture  results.  Prevention  of  transmission  of A.  phagocytophilum  was
demonstrated  by negative  antibody  results  in all sarolaner-treated  dogs.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. IntroductionTicks are vectors for a number of serious disease causing organ-
sms affecting dogs, man  and other animals. Canine Lyme disease,
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caused by Borrelia burgdorferi, and canine anaplasmosis, caused by
Anaplasma phagocytophilum, are bacterial diseases transmitted by
ticks that can affect humans and animals wherever the vector and
a pathogen reservoir is present. These pathogens are transmitted
by various Ixodes tick species in different parts of the world. In
the United States the primary vector is Ixodes scapularis, with the
exception of the paciﬁc coast where it is I. paciﬁcus. Ixodes ricinus is
the primary vector for both organisms in Europe (Chomel, 2011).
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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n Asia, Ixodes persulcatus is a vector for both organisms, and Der-
acentor silvarum is also a vector for A. phagocytophilum (Chomel,
011).
Infection with either B. burgdorferi or A. phagocytophilum can
ause a variety of clinical signs in dogs, ranging from asymptomatic
ub-clinical infection to acute life-threatening or chronic condi-
ions, and co-infection can increase the incidence and severity
f these signs (Beall et al., 2006; Littman et al., 2006). I. scapu-
aris can be found throughout the northeastern, north central,
outheastern and south central United States (Dennis et al., 1998;
rownstein et al., 2003), and appears to be expanding into new
reas (Ogden et al., 2009). In endemic Lyme areas, prevalences of B.
urgdorferi and A. phagocytophilum in I. scapularis adults of 50.3%
nd 61%, respectively, have been demonstrated (Schulze et al.,
005). Because of the increasing recognition of the importance of
nfections with tick-borne pathogens on the health of dogs, it is
urrently recommended that pet owners take measures to reduce
ick populations in the dogs’ environment, frequently examine and
mmediately remove any ticks found on the dog, and to use an
pproved product year-round to protect dogs against unexpected
xposure to ticks (Companion Animal Parasite Council, 2015).
Sarolaner (SimparicaTM, Zoetis) is a new isoxazoline that has
een developed for the treatment and month long control of ticks
nd ﬂeas on dogs following a single oral dose (McTier et al., 2016).
aboratory studies conﬁrmed that sarolaner was effective for the
ntire month against the major species of ticks infesting dogs in
urope and the United States (Geurden et al., 2016; Six et al., 2016a).
he current study was conducted to evaluate the efﬁcacy of a sin-
le oral treatment of sarolaner at a dosage of 2 mg/kg to protect
ogs primarily from B. burgdorferi and secondarily from A. phago-
ytophilum infections transmitted by I. scapularis.
. Materials and methods
This laboratory study was conducted in the United States in
ccordance with the World Association for the Advancement of Vet-
rinary Parasitology (WAAVP) guidelines for evaluating the efﬁcacy
f parasiticides for the treatment, prevention and control of ﬂea and
ick infestation on dogs and cats (Marchiondo et al., 2013) and com-
lied with Good Clinical Practices (EMEA., 2000). The study protocol
as reviewed and approved by the Zoetis Institutional Animal Care
nd Use Committee.
.1. Animals
Purpose bred, Beagles obtained from a commercial supplier
ere used. The 12 male and 12 female dogs ranged in age from 11
o 13 months, and weighed between 6.0 and 13.3 kg at the time of
reatment. Each dog was uniquely identiﬁed by an ear tattoo. Dogs
ad not been previously infested with ticks, vaccinated against B.
urgdorferi, nor used in any experimental evaluation.
Dogs were housed individually in indoor stainless steel raised
uns approximately 4 feet by 6 feet with tender-foot ﬂooring.
nclosures conformed to accepted animal welfare guidelines and
nsured no direct contact between dogs. Dogs were fed an appro-
riate maintenance ration of a commercial dry canine feed for the
uration of the study. Water was available ad libitum.  From Day
 (the day of ﬁrst study treatment) to the end of the study, study
articipants handling dogs used separate protective clothing (e.g.,
aboratory coat, coveralls or apron, disposable gloves, and booties)
or dogs in each treatment group..2. Masking
All study personnel who were involved in post-treatment health
bservations, tick counts, selection of biopsy sites, biopsy col-arasitology 222 (2016) 67–72
lection, serology analysis, and tissue analysis were unaware of
treatment allocation.
2.3. Health observations
A physical exam was performed on each dog by a veterinarian
to determine health and suitability prior to inclusion in the study.
Dogs were assessed at least twice daily for the duration of the study
for signs of abnormal health. Dogs were examined at 1, 3, 6, and
24 h after each treatment for possible adverse reactions. Beginning
six days after infestation with ticks, daily observations included
evaluation for clinical signs speciﬁc to tick-borne disease, including
but not limited to lameness, ataxia and lethargy.
2.4. Allocation to treatment
Dogs were ranked within sex by decreasing body weight into
blocks of three and randomly allocated to one of three treatment
groups: placebo administered on Days 0 and 7, sarolaner admin-
istered on Day 0 (28 days prior to tick infestation), or sarolaner
administered on Day 7 (21 days prior to tick infestation). To main-
tain masking, placebo was  administered to dogs in the sarolaner
groups on days when sarolaner was not administered. Blocks of
dogs were randomly assigned to adjacent pens within the test facil-
ity. Dogs were moved into their allocated pens on Day -2.
2.5. Treatment administration
The commercial SimparicaTM chewable tablet formulation was
used. The placebo formulation was  similar to the active formula-
tion, but did not contain sarolaner. For dogs in the sarolaner-treated
groups, 40 mg  sarolaner tablets were shaved and/or sanded based
on each dog’s individual bodyweight to deliver a sarolaner dosage
of 2.0 mg/kg. Dogs in the placebo-treated group received a single
placebo tablet that matched the active 40 mg  tablet in size and
appearance. Dogs were hand pilled to ensure accurate and com-
plete dose delivery. Each dog was observed for several minutes to
ensure the dose was  swallowed and then periodically for up to two
hours for signs of emesis.
2.6. Ticks
Adult I. scapularis ticks were collected from Lyme endemic
regions in Rhode Island between October and November, 2012.
Ticks were maintained at 5–15 ◦C under saturated humidity condi-
tions for 4–8 weeks until used to infest the dogs. A random sample
of 30 adult I. scapularis female and male ticks of this ﬁeld collected
population was tested by PCR for the presence of B. burgdorferi and
A. phagocytophilum DNA using published methods (McCall et al.,
2011).
2.7. Tick infestation and counting
On Day 28, a pre-counted aliquot of approximately 25 female
and 25 male adult I. scapularis were placed onto the hair coat of
each dog and allowed to disperse. Following infestation, dogs were
placed in travel crates in a darkened room for approximately six
hours to enhance tick attachment.
Tick counts were performed by personnel trained in the stan-
dard procedures in use at the test facility. On Days 29 and 30, the
numbers of live ticks (attached and free) were determined in situ by
careful and systematic examination of the entire dog’s body and by
pushing the hair against its natural nap to expose ticks. On Day 33,
ticks were counted and removed. After the manual inspection, an
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xtra-ﬁne tooth comb (commercial ﬂea comb) was used to comb
he dog to remove any otherwise missed ticks.
.8. Sample collection and testing
.8.1. Blood
Blood samples were collected from each dog on Days -6, 27, 49,
3, 77, 91 and 104 (i.e., before treatment, before tick infestation,
nd at 21, 35, 49, 63, and 76 days after tick infestation).
At each time point, serum was separated from each sample and
n aliquot assayed using the SNAP® 4Dx® Plus test (IDEXX Labora-
ories, Inc., Westbrook, Maine, USA) using the procedures described
n the package insert. The SNAP® 4Dx® Plus Test kit is an ELISA
or simultaneous detection of canine antibodies to Ehrlichia canis,
hrlichia ewingii,  B. burgdorferi, A. phagocytophilum, and A. platys,
nd for Diroﬁlaria immitis antigen. Sensitivity of this test for B.
urgdorferi has been reported to be 94.4% when compared to a com-
ination of immunoﬂuorescence assay and Western blot (O’Connor
t al., 2004), and the speciﬁcity to be 99.5% (Duncan et al., 2004). The
. phagocytophilum sensitivity and speciﬁcity have been reported
o be 99.1% and 100%, respectively, relative to the immunoﬂuores-
ence assay (Chandrashekar et al., 2007).
A second aliquot of serum was tested for B. burgdorferi quanti-
ative antibody levels to OspA by ELISA. Brieﬂy, 96-well microtiter
lates were coated with recombinant puriﬁed OspA antigen in
.01 M Borate buffer and incubated overnight at 4 ◦C. After dis-
arding the coating solution, plates were blocked with 200 L 1%
asein in PBS containing 0.05% Tween 20® and incubated at 37 ◦C
or 60 (±5) min. Blocked plates were washed three times with
BS-Tween 20®. Test serum samples were diluted in PBS-Tween
0® to the appropriate start dilution. Positive and negative con-
rol samples (OspA) were diluted accordingly. After transferring
he test and control samples to the test plate, plates were incu-
ated at 37 ◦C for 60 (±5) min. Plates were washed for three times
ith PBS-Tween 20®. Conjugate [goat anti-dog IgG(H + L) antibody,
eroxidase labeled] was diluted to the appropriate dilution in PBS-
ween 20® and added to each well. Plates were incubated at 37 ◦C
or 60 (±5) min  and then washed for three times with PBS-Tween
0®. ABTS substrate was prepared and added to each well and plates
ere incubated for 10–15 min  at room temperature. Optical densi-
ies (OD) were determined and test sample titers were calculated
rom the average plus three standard deviations of the negative
ontrol OD value. Test sample dilutions above the negative con-
rol OD represented the end point titer. Testing was  repeated if the
ositive or negative controls were not in the expected range.
.8.2. Skin biopsies
On Day 33, after all ticks were removed, the hair from the four
reas with the highest number of attached ticks or with the most
otable inﬂammation from an attached tick on each dog was  shaved
o identify the sites for future biopsy. If an area of the face, ears or
ead was one of the identiﬁed sites, an area of the dog’s neck close
o the site was  shaved to reduce animal discomfort. If less than four
reas of tick attachment or inﬂammation were present, up to four
f the most common areas of tick attachment or inﬂammation from
ogs with infestations were shaved so that a total of four sites were
haved on each dog. To maintain site location, the same sites were
haved again on Days 49, 63, 77, 91 and 104.
On Day 104, two 4.0 mm punch skin biopsies were collected
rom each of the four shaved locations using standard aseptic sur-
ical procedures. One biopsy from each site was used for bacterial
ulture and PCR testing, and the second sample was  stored at ≤20 ◦C
s a backup.rasitology 222 (2016) 67–72 69
Skin biopsies were cultured to isolate B. burgdorferi and tested
for the presence of B. burgdorferi DNA by PCR using published meth-
ods (Nocton et al., 1994; Chang et al., 2001).
2.9. Data analysis
The individual dog was  the experimental unit. Statistical analy-
ses were performed using SAS 9.2 (SAS, Cary NC).
2.9.1. Tick counts
Live tick counts were subjected to the loge(count +1) trans-
formation prior to analysis in order to stabilize the variance and
normalize the data. Using the PROC MIXED procedure, transformed
live tick counts (attached and free) were analyzed using a mixed
linear model for repeated measures. The model included the ﬁxed
effects of sex, treatment, day of study and the interaction among
those effects. The random effects included block within sex, the
interaction between block and treatment within sex (animal term)
and error. A Priori contrasts were used to assess pair-wise compar-
isons between treatments at each time point.
No interactions involving both sex and time point were sig-
niﬁcant, but there were signiﬁcant treatment effects therefore
treatment differences were assessed at each time point. Testing
was two-sided at the signiﬁcance level =0.05. Percent efﬁcacy,
relative to the placebo group was  calculated as follows:
%Efﬁcacy = (Geometric Mean Placebo - Geometric Mean Treated)
Geometric Mean Placebo
× 100
2.9.2. B. burgdorferi antibody, culture and PCR, and A.
phagocytophilum antibody
Frequency distributions of positive/negative antibodies, cul-
tures and PCR for B. burgdorferi and antibodies for A. phagocy-
tophilum were calculated for each treatment at each time point.
Frequency distributions of ‘ever positive’ (a dog was  deﬁned as
being ‘ever positive’ if it ever tested positive for B. burgdorferi by
the presence of antibodies, or positive culture, or positive PCR test)
for B. burgdorferi and positive for A. phagocytophilum antibody were
calculated for each treatment and a Fisher’s exact test was used to
test for overall treatment effects and treatment differences.
2.9.3. Quantitative B. burgdorferi antibody titers by ELISA
Antibody titers were transformed loge(titer) prior to analysis.
The transformed titers were analyzed with a general linear mixed
model for repeated measures. The model included the ﬁxed effects
of sex, treatment, time point and all interactions among those
effects. The random effects included block within sex, the inter-
action of block and treatment within sex (animal term), and error.
Mean centered Day -6 loge(titer) data was used as a covariate for
the repeated measures model for log transformed antibody titers to
adjust for differences in log transformed titers prior to treatment.
No interactions involving both sex and time point were sig-
niﬁcant, but there were signiﬁcant treatment effects therefore
treatment differences were assessed at each time point. All tests
were done at the two-tailed 5% level of signiﬁcance. Least squares
means at each time point and 95% conﬁdence intervals were
back-transformed to obtain the geometric means and their corre-
sponding conﬁdence intervals.
3. Results3.1. Live I. scapularis counts and infection prevelance
PCR analysis of a random sample of 30 ticks from the study pop-
ulation conﬁrmed prevalence rates of 57% for B. burgdorferi and 6.7%
70 N.A. Honsberger et al. / Veterinary Parasitology 222 (2016) 67–72
Table  1
Efﬁcacy of a single oral treatment of sarolaner (2 mg/kg): Live Ixodes scapularis counts, ranges, and number of dogs with ticks.
Live I. scapularis count
Treatment group Time of count after infestation Number of dogs with live ticks Range Geometric mean Percent reduction relative to placebo
Placebo 1 day 8 of 8 12–21 14.8 –
2  days 8 of 8 8–17 12.8 –
5  days 8 of 8 15–25 19.1 –
Sarolaner
28  days prior to infestation
1 day 6 of 8 0–6 1.3* 90.9%
2  days 3 of 8 0–2 0.4* 97.1%
5  days 0 of 8 0–0 0.0* 100%
Sarolaner 1 day 7 of 8 0–5 2.0* 86.3%
2  days 0 of 8 0–0 0.0* 100%
0–0 0.0* 100%
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Fig. 1. Borrelia burgdorferi ELISA titers in dogs treated orally with placebo or21  days prior to infestation
5  days 0 of 8 
* Geometric mean count signiﬁcantly lower than placebo (P < 0.0001).
or A. phagocytophilum. Live ticks were found on all eight placebo-
reated dogs on all count days, with a geometric mean (range) of
4.8 (12–21), 12.8 (8–17), and 19.1 (15–25) live ticks at 1, 2, and 5
ays after infestation, respectively (Table 1). One day after infesta-
ion, live ticks were found on 13 of 16 sarolaner-treated dogs (live
ick count range 0–6), two days after infestation, live ticks were
ound on only three of eight dogs treated 28 days prior to infes-
ation (live tick count range 0–2) and no ticks were found on the
ogs treated 21 days prior to infestation. Five days after infestation,
o live ticks were found on any sarolaner-treated dog. Relative to
lacebo, live tick counts at 1, 2, and 5 days after infestation were
educed by 90.9%, 97.1%, and 100% for dogs treated 28 days prior
o infestation, and by 86.3%, 100%, and 100% for dogs treated 21
ays prior to infestation. Geometric mean live tick counts were
igniﬁcantly lower than placebo on all Days (P < 0.0001).
.2. B. burgdorferi and A. phagocytophilum serum antibody by
NAP® 4Dx® plus
All dogs were negative for antibodies to B. burgdorferi prior to
tudy treatment. B. burgdorferi antibody was detected in six of the
ight placebo dogs on at least one post-infestation day. Two  dogs
ere positive on Day 63, ﬁve on Days 77 and 91, and six on Day
04. None of the 16 sarolaner-treated dogs were positive for B.
urgdorferi antibody at any time-point (Table 2).
All dogs were negative for antibodies to A. phagocytophilum
rior to study treatment. A. phagocytophilum antibody was  detected
n four of the eight placebo dogs on at least one post-infection
ay. One dog was positive on Day 63, and four on Days 77, 91,
nd 104. None of the 16 sarolaner-treated dogs were positive
or A. phagocytophilum antibody at any time point (Table 3). The
umber of sarolaner-treated dogs positive for A. phagocytophilum
ntibody was not signiﬁcantly different from placebo-treated dogs
P = 0.0769).
.3. B. burgdorferi PCR and culture from skin biopsies
In seven of the eight placebo-treated dogs, the presence of B.
urgdorferi in two or more of the four skin biopsy samples was
onﬁrmed by PCR and culture. B. burgdorferi was not detected by
CR or culture in any of the four skin biopsies collected from one of
he placebo-treated dogs (Table 4). B. burgdorferi was  not detected
y PCR or culture in any of the skin biopsies collected from any of
he 16 sarolaner-treated dogs.
.4. Dogs ‘ever positive’ for B. burgdorferiFor placebo-treated dogs, B. burgdorferi antibody was  present
n at least one post-infestation time-point, or B. burgdorferi was
etected by PCR or isolated by culture in at least one skin biopsy.
hus, all eight placebo-treated dogs were ‘ever positive’ for B.sarolaner (2 mg/kg) on Day 0 or 7 and infested with infected Ixodes scapularis on
Day 28. Error bars represent back-transformed 95% conﬁdence intervals.
burgdorferi. For sarolaner-treated dogs, B. burgdorferi antibody was
not detected at any time-point, and B. burgdorferi was not detected
by PCR nor isolated by culture in any of the four skin biopsies. There-
fore none of the sarolaner-treated dogs were ‘ever positive’ for B.
burgdorferi. The number of sarolaner-treated dogs ‘ever positive’
for B. burgdorferi was signiﬁcantly lower than that for the placebo-
treated dogs (P = 0.0002).
3.5. Quantitative B. burgdorferi antibody titers by ELISA
Following tick infestation, antibody titers to B. burgdorferi in
placebo-treated dogs increased markedly, while those for both
sarolaner-treated groups remained generally unchanged (Fig. 1).
Antibody titers for the group treated with sarolaner 21 days prior
to infestation were signiﬁcantly lower than those for the placebo
group on all post-infestation days (P ≤ 0.0078). Antibody titers for
the group treated with sarolaner 28 days prior to infestation were
not signiﬁcantly different than placebo on Day 49 (P = 0.1227), but
were signiﬁcantly lower on all subsequent post-infestation days
(P ≤ 0.0475). Antibody titers for the sarolaner group treated 21
days prior to infestation were not signiﬁcantly different than those
for the group treated 28 days prior to infestation on any post-
infestation day (P ≥ 0.0552).
3.6. Health observations
There were no adverse events related to treatment with
sarolaner. One placebo-treated dog was  noted to have forelimb
lameness on Days 64 and 92. Both occurrences responded to symp-
tomatic treatment with oral carprofen.
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Table  2
SNAP® 4Dx® Plus test results for Borrelia burgdorferi antibody in dogs treated orally with placebo or sarolaner (2 mg/kg) on Day 0 or 7 and infested with infected Ixodes
scapularis on Day 28.
Borrelia burgdorferi antibody negative (−)/positive (+)
Treatment group Animal Day -6 Day 27 Day 49 Day 63 Day 77 Day 91 Day 104
Placebo 1879066 − − − − + + +
1892208 − − − + + + +
1901011 − − − − + + +
1908040 − − − + + + +
1908538 − − − − − – +
1909241 − − − − + + +
1909577 − − − − − − −
1911962 − − − − − − −
Sarolaner21 or 28 days prior to infestation All sarolaner-treated dogs were negative for B. burgdorferi antibody on all Days
Table 3
SNAP® 4Dx® Plus test results for Anaplasma phagocytophilum antibody in dogs treated orally with placebo or sarolaner (2 mg/kg) on Day 0 or 7 and infested with infected
Ixodes  scapularis on Day 28.
Anaplasma phagocytophilum antibody negative (−)/positive (+)
Treatment group Animal Day-6 Day 27 Day 49 Day 63 Day 77 Day 91 Day 104
Placebo 1879066 − − − − + + +
1892208 − − − − − − −
1901011 − − − − − − −
1908040 − − − + + + +
1908538 − − − − − − −
1909241 − − − − + + +
1909577 − − − − − − −
1911962 − − − − + + +
Sarolaner21 or 28 days prior to infestation All sarolaner-treated dogs were negative for A. phagocytophilum antibody on all Days
Table 4
Borrelia burgdorferi PCR and culture results from skin biopsies collected on Day 104 (76 days after infestation with infected Ixodes scapularis on Day 28) from dogs treated
orally  with placebo or sarolaner (2 mg/kg).
Borrelia burgdorferi PCR and culture results negative (−)/positive (+)
Biopsy site 1 Biopsy site 2 Biopsy site 3 Biopsy site 4
Treatment group Animal PCR Culture PCR Culture PCR Culture PCR Culture
Placebo 1879066 + + + + + + − −
1892208 + + + + − − − −
1901011 + + + + + + − −
1908040 + + + + + + − −
1908538 + + + + − − + −
1909241 − − − − − − − −
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Sarolaner21 or 28 days prior to infestation Skin biopsies collected from sa
. Discussion
B. burgdorferi was successfully transmitted to all eight placebo-
ontrol dogs, but not to any of the sarolaner-treated dogs. Despite
he markedly lower prevalence of A. phagocytophilum (∼10% of that
or B. burgdorferi), four of the eight placebo-control dogs became
nfected. Although not signiﬁcantly different to the placebo-control
roup, A. phagocytophilum was not transmitted to any of the
arolaner-treated dogs. Therefore in this study, sarolaner protected
ogs against the transmission of B. burgdorferi and A. phagocy-
ophilum when exposed to infected I. scapularis ticks up to 28 days
fter treatment.
The time required for a tick to feed before pathogen transmis-
ion occurs is dependent on many factors, and varies between tick
pecies and disease agents. Laboratory studies have shown that I.
capularis only occasionally transmits B. burgdorferi before 24–48 h
f feeding, and that transmission occurs to a greater extent with
onger feeding periods (Kidd and Breitschwerdt, 2003). This period
f time between initiation of feeding and pathogen transmission
s likely a result of the time it takes for the organism to migrate+ + + + + +
+ + + + − −
r-treated dogs were negative for B. burgdorferi by PCR and bacterial culture
within the tick from the mid  gut to the salivary glands where it can
be transmitted via saliva during feeding (de Silva and Fikrig, 1995;
Piesman, 1995; Schwan and Piesman, 2000). A. phagocytophilum
has been found in the salivary glands of unfed I. scapularis, and
therefore it is postulated that it is more likely to be quickly trans-
mitted (de Silva and Fikrig, 1995; Kidd and Breitschwerdt, 2003).
However, transmission times demonstrated in laboratory studies
with mice have been variable, ranging from less than 24 to more
than 40 h (Kidd and Breitschwerdt, 2003).
In a study conducted to evaluate the speed of kill of a single oral
dose of sarolaner at a dosage of 2 mg/kg against I. scapularis, live tick
counts were signiﬁcantly reduced relative to placebo at eight hours
after treatment, and efﬁcacy reached 98.8% at 12 h, and was 100%
at 24 h post-treatment (Six et al., 2016b). A rapid speed of kill was
maintained throughout the month with ≥95.7% efﬁcacy at 24 h after
re-infestation for 28 days. This rapid speed of kill, combined with
the prevention of pathogen transmission observed in the current
study suggests that the infected I. scapularis ticks were killed before
B. burgdorferi and A. phagocytophilum transmission could occur.
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Wengenmayer, C., Williams, H., Zschiesche, E., Moritz, A., Langenstein, J., Roepke,2 N.A. Honsberger et al. / Veterin
The ability of a topical application of ﬁpronil, amitraz, and (S)-
ethoprene to prevent the transmission of B. burgdorferi and A.
hagocytophilum from infected I. scapularis to dogs has been previ-
usly reported (McCall et al., 2011). One of the perceived beneﬁts
f topically applied acaricidal products is that ticks will be killed
efore attachment and commencement of feeding, therefore reduc-
ng the risk of pathogen transmission. The results of the current
tudy indicate that an orally administered acaricide with a consis-
ent and rapid speed of kill can also reduce the risk of tick-borne
athogen transmission.
In order to reduce the risk of tick-borne disease, it is recom-
ended that pet owners take steps to reduce pet exposure to
icks, including the year-round use of approved ectoparasiticides
o protect pets from unexpected tick exposure. The recommenda-
ion for year-round use is especially important with regards to I.
capularis, because the adults are most active and likely to feed on
ogs in the cooler months, when the need for ectoparasite con-
rol might not typically be considered. Laboratory studies have
onﬁrmed the efﬁcacy of sarolaner for the entire month against
he major species of ticks infesting dogs in Europe and the United
tates (Geurden et al., 2016; Six et al., 2016a). As the speed of kill
nd consequent interruption of feeding is critical to reduce the risk
f tick-borne pathogen transmission, laboratory studies were also
onducted to evaluate the speed of kill of sarolaner against I. rici-
us and A. maculatum (Six et al., 2016b). Following treatment, live
ick counts were signiﬁcantly reduced relative to placebo at eight
ours post treatment, reached 90.1% against I. ricinus and 99.2%
gainst A. maculatum within 12 h, and provided 100% efﬁcacy at
4 h after treatment against both species. This rapid speed of kill
as maintained throughout the month with ≥98.7% and ≥89.6%
fﬁcacy against I. ricinus and A. maculatum, respectively, at 24 h
fter re-infestation at least through Day 28.
An initial attachment and feeding of at least 24–48 h is required
efore transmission of most tick-borne pathogens can occur
Salinas et al., 2010; Little et al., 2014). If the infected ticks are
illed within that time period, the transmission may  be prevented
Wengenmayer et al., 2014). With its rapid speed of kill and sus-
ained high efﬁcacy within 24 h for a full month after a single dose,
arolaner is likely to effectively reduce the chances of ticks surviv-
ng and/or feeding for this critical time period. Therefore the use of
arolaner in a tick-control program should reduce the risk of dogs
ecoming infected with tick-borne diseases as well as minimize the
eleterious health effects associated with tick infestation.
. Conclusions
In this controlled laboratory study, a single oral dose of
arolaner (SimparicaTM) successfully prevented the transmission
f B. burgdorferi and A. phagocytophilum from infected wild-caught
. scapularis to dogs for 28 days.
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